We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Testicular Cancer Detected Using a Simple Sperm Sample

By LabMedica International staff writers
Posted on 07 Jun 2012
A team of scientists has found markers for testicular cancer. More...
This will enable physicians to detect the disease before it develops, via a simple sperm sample.

Discovery of the markers has made it possible to see from a simple sperm sample whether a patient will develop testicular cancer. Thus, treatment can be provided for men who would otherwise not have found the disease until much later, and a more gentle treatment can begin at an earlier stage.

This is beneficial particularly for men with testicular cancer, because they usually discover the disease in their 20s or 30s, which means they have a long life ahead of them with possible late complications from cancer treatment.

Men with poor sperm quality, in particular, those who consult the hospital because of fertility problems, are being examined to detect possible early stages of testicular cancer. According to the investigators, poor sperm quality and predisposition to testicular cancer can be traced all the way back to fetal germ-cell development.

A research team at Rigshospitalet (Copenhagen, Denmark) has developed a special scanning microscope and software, which can analyze sperm samples. The discovery has attracted much attention from colleagues abroad.

"So far, we are cooperating with researchers in Norway, Germany, and Poland, who can make use of our discovery in different ways. The equipment is expensive, so to begin with we are helping by analyzing their samples, but in the long term we would like to join up with a company that can supply a total kit for use by other researchers and physicians in different European countries," said Kristian Almstrup from the department of growth and reproduction at Rigshospitalet.

Previously, suspicion of testicular cancer meant that a patient was subjected to one or two painful biopsies, and despite a 95% survival rate, the testicular cancer diagnosis meant having to go through treatment that could be extremely hard on the body.

Related Links:
Rigshospitalet




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.